Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.65 Million SEK | -0.23% |
| 2022 | 14.68 Million SEK | -61.64% |
| 2021 | 38.28 Million SEK | -52.97% |
| 2020 | 81.4 Million SEK | 0.21% |
| 2019 | 81.23 Million SEK | 57.44% |
| 2018 | 51.59 Million SEK | 58.61% |
| 2017 | 32.53 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 2.56 Million SEK | 0.0% |
| 2023 FY | 14.21 Million SEK | -3.2% |
| 2023 Q1 | 4.76 Million SEK | 45.69% |
| 2023 Q2 | 4.76 Million SEK | 0.0% |
| 2023 Q3 | 2.56 Million SEK | -46.15% |
| 2022 Q3 | 3.26 Million SEK | -17.94% |
| 2022 Q1 | 4.02 Million SEK | -45.86% |
| 2022 FY | 14.68 Million SEK | -61.64% |
| 2022 Q4 | 3.26 Million SEK | 0.0% |
| 2022 Q2 | 3.98 Million SEK | -1.02% |
| 2021 Q2 | 16.01 Million SEK | 136.34% |
| 2021 Q3 | 8.06 Million SEK | -49.64% |
| 2021 Q4 | 7.43 Million SEK | -7.82% |
| 2021 FY | 38.28 Million SEK | -52.97% |
| 2021 Q1 | 6.77 Million SEK | -72.8% |
| 2020 Q2 | 17.84 Million SEK | -15.52% |
| 2020 FY | 81.4 Million SEK | 0.21% |
| 2020 Q4 | 24.91 Million SEK | 42.07% |
| 2020 Q3 | 17.53 Million SEK | -1.72% |
| 2020 Q1 | 21.11 Million SEK | 2.68% |
| 2019 Q2 | 28.12 Million SEK | 161.58% |
| 2019 Q1 | 10.75 Million SEK | -47.5% |
| 2019 FY | 81.23 Million SEK | 57.44% |
| 2019 Q4 | 20.56 Million SEK | -5.6% |
| 2019 Q3 | 21.78 Million SEK | -22.55% |
| 2018 Q1 | 5 Million SEK | -32.06% |
| 2018 FY | 51.59 Million SEK | 58.61% |
| 2018 Q4 | 20.48 Million SEK | 39.9% |
| 2018 Q3 | 14.64 Million SEK | 27.62% |
| 2018 Q2 | 11.47 Million SEK | 129.3% |
| 2017 Q4 | 7.36 Million SEK | 107.26% |
| 2017 FY | 32.53 Million SEK | 0.0% |
| 2017 Q1 | 10.8 Million SEK | 0.0% |
| 2017 Q3 | 3.55 Million SEK | -67.12% |
| 2017 Q2 | 10.8 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | 62.08% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 95.442% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 95.903% |
| Xintela AB (publ) | 57.31 Million SEK | 74.435% |
| Active Biotech AB (publ) | 44.8 Million SEK | 67.299% |
| Amniotics AB (publ) | 29.07 Million SEK | 49.598% |
| BioArctic AB (publ) | 89.62 Million SEK | 83.651% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.032% |
| Camurus AB (publ) | 1.05 Billion SEK | 98.617% |
| Cantargia AB (publ) | 290.01 Million SEK | 94.948% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 33.076% |
| CombiGene AB (publ) | 44.14 Million SEK | 66.806% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 89.752% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 48.271% |
| Genovis AB (publ.) | 88.19 Million SEK | 83.386% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 87.266% |
| Mendus AB (publ) | 129.13 Million SEK | 88.653% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -101.61% |
| Intervacc AB (publ) | 79.78 Million SEK | 81.634% |
| Kancera AB (publ) | 63.07 Million SEK | 76.77% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -165.501% |
| LIDDS AB (publ) | 27.75 Million SEK | 47.2% |
| Lipum AB (publ) | 37.3 Million SEK | 60.723% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -101.999% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 89.219% |
| NextCell Pharma AB | -576.01 Thousand SEK | 2643.84% |
| OncoZenge AB (publ) | 15.9 Million SEK | 7.872% |
| Saniona AB (publ) | 1.07 Million SEK | -1260.538% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 91.937% |
| Ziccum AB (publ) | 27.87 Million SEK | 47.439% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 10.658% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 95.228% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 65.629% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 17.135% |
| Corline Biomedical AB | 30.16 Million SEK | 51.429% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 74.75% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 82.382% |
| Aptahem AB (publ) | 10.01 Million SEK | -46.341% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 89.121% |
| Fluicell AB (publ) | 28.61 Million SEK | 48.796% |
| Biovica International AB (publ) | 133.72 Million SEK | 89.042% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 25.958% |
| AcouSort AB (publ) | 25.87 Million SEK | 43.372% |
| Abliva AB (publ) | 27.86 Million SEK | 47.416% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 92.427% |
| 2cureX AB (publ) | 36.51 Million SEK | 59.875% |
| I-Tech AB | 40.14 Million SEK | 63.503% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 98.295% |
| Cyxone AB (publ) | 28.21 Million SEK | 48.065% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 86.602% |
| Biosergen AB | 26.8 Million SEK | 45.343% |
| Nanologica AB (publ) | 69.88 Million SEK | 79.033% |
| SynAct Pharma AB | 224.49 Million SEK | 93.473% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 66.83% |
| BioInvent International AB (publ) | 441.4 Million SEK | 96.68% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 38.829% |
| Alzinova AB (publ) | 36.39 Million SEK | 59.74% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 94.943% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -86.513% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 86.789% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 0.32% |